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Background: Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with systolic heart failure (HF), but may induce a 
worsening of renal function (WRF) and/or an increase in serum potassium concentrations. We aimed at assessing the incidence and risk factors of 
MRA-related WRF and hyperkalemia (HK) as well as their association with clinical outcomes in the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF).
Methods: Serial changes in estimated glomerular filtration rate (eGFR) and in serum potassium were available in 2,737 patients during a median 
21-month follow-up. WRF was defined as any episode of decrease in eGFR>20% from baseline, and HK as any episode of serum K>5.5 mmol/L. 
Results: Patients assigned eplerenone had a significant rise in serum potassium (+0.12 mmol/L (CI95: 0.06-0.19, p=0.0001), with an early 
eGFR decline (-1.57 to 2.56 ml/min/1.73m2, p<0.05 during the first 21 months). Serum potassium and eGFR variations were weakly interrelated. 
Incidence of WRF (52% vs. 46.7%, p= 0.002) and HK (16.7% vs. 10.7%, p=0.0003) were common, and more so in the eplerenone (vs. placebo) 
group. In multivariate analysis, WRF incidence was positively associated with incident HK, higher baseline eGFR, use of eplerenone, loop diuretics, 
antiarrhytmics, age, lower ejection fraction, diabetes and negatively with higher baseline serum potassium. Incidence of HK was positively associated 
with history of hypertension, eplerenone use, higher baseline serum potassium and lower baseline eGFR. HK but not WRF was associated with worse 
clinical outcomes, independent of lower baseline eGFR and of eplerenone use, which retained its prognostic benefits.
Conclusions: WRF and HK were common in HF patients on standard medical therapy. Their risk factors can be identified, making both potentially 
preventable. Eplerenone retained its clinical benefit despite being associated with more frequent WRF and HK.
